ST-271

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H581015

CAS#: 106392-48-7

Description: ST-271 is tyrphostin tyrosine kinase inhibitor. ST271 reduced intracellular Ca2+ levels and inhibited activation of phospholipase C. Elevation of intracellular Ca2+ regulates agonist-induced activation of phospholipase C and that this contributes to the inhibition of thrombin-induced formation of inositol phosphates by the tyrphostin ST271.

Chemical Structure

img
ST-271
CAS# 106392-48-7
Instruction

Theoretical Analysis

Hodoodo Cat#: H581015
Name: ST-271
CAS#: 106392-48-7
Chemical Formula: C16H20N2O2
Exact Mass: 272.15
Molecular Weight: 272.340
Elemental Analysis: C, 70.56; H, 7.40; N, 10.29; O, 11.75

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ST-271; ST271; ST 271.

IUPAC/Chemical Name: (E)-2-Cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]prop-2-enamide

InChi Key: HMLQHJRJKQDTKW-LFYBBSHMSA-N

InChi Code: InChI=1S/C16H20N2O2/c1-9(2)13-6-11(5-12(8-17)16(18)20)7-14(10(3)4)15(13)19/h5-7,9-10,19H,1-4H3,(H2,18,20)/b12-5+

SMILES Code: O=C(N)/C(C#N)=C/C1=CC(C(C)C)=C(O)C(C(C)C)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 272.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hjálmarsdóttir MÁ, Kristinsson KG. Epidemiology of penicillin-non-susceptible pneumococci in Iceland, 1995-2010. J Antimicrob Chemother. 2014 Apr;69(4):940-6. doi: 10.1093/jac/dkt470. Epub 2013 Dec 5. PubMed PMID: 24311742.

2: Bean DC, Klena JD. Characterization of major clones of antibiotic-resistant Streptococcus pneumoniae in New Zealand by multilocus sequence typing. J Antimicrob Chemother. 2005 Mar;55(3):375-8. Epub 2005 Jan 28. PubMed PMID: 15681581.

3: Ohno R. [Tyrosine kinase inhibitor--hematological malignancies]. Gan To Kagaku Ryoho. 2001 May;28(5):601-7. Review. Japanese. PubMed PMID: 11383207.

4: Wheeler-Jones CP, May MJ, Morgan AJ, Pearson JD. Protein tyrosine kinases regulate agonist-stimulated prostacyclin release but not von Willebrand factor secretion from human umbilical vein endothelial cells. Biochem J. 1996 Apr 15;315 ( Pt 2):407-16. PubMed PMID: 8615807; PubMed Central PMCID: PMC1217210.

5: Poole AW, Watson SP. Regulation of cytosolic calcium by collagen in single human platelets. Br J Pharmacol. 1995 May;115(1):101-6. PubMed PMID: 7647963; PubMed Central PMCID: PMC1908739.

6: Watson SP, Poole A, Asselin J. Ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) and the tyrphostin ST271 inhibit phospholipase C in human platelets by preventing Ca2+ entry. Mol Pharmacol. 1995 Apr;47(4):823-30. PubMed PMID: 7723744.

7: Rodríguez-Liñares B, Watson SP. Phosphorylation of JAK2 in thrombin-stimulated human platelets. FEBS Lett. 1994 Oct 3;352(3):335-8. PubMed PMID: 7925997.

8: Martinson EA, Scheible S, Presek P. Inhibition of phospholipase D of human platelets by protein tyrosine kinase inhibitors. Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):627-34. PubMed PMID: 7526916.

9: Blake RA, Asselin J, Walker T, Watson SP. Fc gamma receptor II stimulated formation of inositol phosphates in human platelets is blocked by tyrosine kinase inhibitors and associated with tyrosine phosphorylation of the receptor. FEBS Lett. 1994 Mar 28;342(1):15-8. PubMed PMID: 8143842.

10: Pettitt TR, Zaqqa M, Wakelam MJ. Epidermal growth factor stimulates distinct diradylglycerol species generation in Swiss 3T3 fibroblasts: evidence for a potential phosphatidylcholine-specific phospholipase C-catalysed pathway. Biochem J. 1994 Mar 15;298 Pt 3:655-60. PubMed PMID: 8141780; PubMed Central PMCID: PMC1137910.

11: Shiraishi T, Owada MK, Tatsuka M, Yamashita T, Watanabe K, Kakunaga T. Specific inhibitors of tyrosine-specific protein kinases: properties of 4-hydroxycinnamamide derivatives in vitro. Cancer Res. 1989 May 1;49(9):2374-8. PubMed PMID: 2706625.